Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of the VA-funded MDMA therapy study by end of 2025?
Effective for both PTSD and alcohol use disorder • 25%
Effective only for PTSD • 25%
Effective only for alcohol use disorder • 25%
Not effective for either condition • 25%
Publication of study results in a peer-reviewed journal or official VA report
VA Funds $1.5 Million Study on Psychedelic Therapy for PTSD and Alcohol Use Disorder, First in Over 50 Years
Dec 3, 2024, 05:58 PM
Recent developments in psychedelic therapy research indicate a growing interest in the use of psilocybin and MDMA for treating various mental health conditions. A new research review suggests that psilocybin therapy may effectively address both alcohol use disorder and depression simultaneously, highlighting the interconnectedness of these conditions. Concurrently, the U.S. Department of Veterans Affairs has announced a $1.5 million funding initiative for a study on psychedelic-assisted therapy, marking the first VA-funded research in over 50 years. This study will focus on MDMA-assisted therapy for veterans suffering from PTSD and alcohol use disorder. In addition, states like Oregon and Colorado are leading the way in psychedelic legalization, permitting supervised psilocybin use, although high costs ranging from $1,500 to $5,000 per session limit accessibility. Other states are also considering similar legislation as bipartisan support for therapeutic use of psychedelics grows, while the FDA continues to review these substances as potential breakthrough therapies.
View original story
Significant positive results • 25%
Moderate positive results • 25%
No significant results • 25%
Negative results • 25%
Study shows significant positive results • 25%
Study shows moderate positive results • 25%
Study shows no significant effect • 25%
Study shows negative results • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened condition • 25%
Approved without restrictions • 25%
Approved with restrictions • 25%
Rejected • 25%
Decision delayed • 25%
Significant positive impact • 25%
Moderate positive impact • 25%
No significant impact • 25%
Negative impact • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
2 or fewer states • 25%
More than 10 states • 25%
6-10 states • 25%
3-5 states • 25%
Other • 25%
California • 25%
Washington • 25%
New York • 25%